FY2025 · ended Dec 31, 2025 · Revenue $7.95M, +123.6% YoY · Filed Mar 16, 2026
Coya Therapeutics, Inc. (COYA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.9 million and a net loss of $21.2 million.
Revenue (TTM)
$8.02M
+1793.8% vs year-ago TTM
Net income (TTM)
$-21.67M
-6.5% vs year-ago TTM
Operating cash flow (TTM)
$-15.72M
+4.6% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.09
+12.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
23.46M
+40.3% vs prior year
Net cash
—
Operating margin
-288.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M |
| Diluted EPS | -$1.27 | -$0.98 | -$0.79 | -$4.73 |
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M |
| Stockholders' equity | $43.0M | $39.6M | $35.6M | -$8.4M |
| Cash and investments | $46.8M | $38.3M | $32.6M | $5.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Aug 7, 2026 | Mar 29, 2026 |
All 230 Coya Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.